nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—CYP3A5—Teniposide—lymphatic system cancer	0.158	0.188	CbGbCtD
Alfentanil—CYP3A7—Vincristine—lymphatic system cancer	0.102	0.12	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.102	0.12	CbGbCtD
Alfentanil—CYP3A5—Vincristine—lymphatic system cancer	0.0763	0.0903	CbGbCtD
Alfentanil—ABCB1—Mitoxantrone—lymphatic system cancer	0.0721	0.0854	CbGbCtD
Alfentanil—CYP3A4—Cytarabine—lymphatic system cancer	0.0627	0.0743	CbGbCtD
Alfentanil—CYP3A4—Teniposide—lymphatic system cancer	0.0618	0.0731	CbGbCtD
Alfentanil—ALB—Methotrexate—lymphatic system cancer	0.0574	0.068	CbGbCtD
Alfentanil—ABCB1—Vincristine—lymphatic system cancer	0.0496	0.0588	CbGbCtD
Alfentanil—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0432	0.0512	CbGbCtD
Alfentanil—ABCB1—Methotrexate—lymphatic system cancer	0.03	0.0356	CbGbCtD
Alfentanil—CYP3A4—Vincristine—lymphatic system cancer	0.0297	0.0352	CbGbCtD
Alfentanil—Myoclonus—Vincristine—lymphatic system cancer	0.00329	0.0212	CcSEcCtD
Alfentanil—Injection site pain—Carmustine—lymphatic system cancer	0.00254	0.0163	CcSEcCtD
Alfentanil—Visual disturbance—Fludarabine—lymphatic system cancer	0.00248	0.016	CcSEcCtD
Alfentanil—Bronchospasm—Teniposide—lymphatic system cancer	0.00227	0.0146	CcSEcCtD
Alfentanil—Disorientation—Bleomycin—lymphatic system cancer	0.00193	0.0124	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00185	0.0119	CcSEcCtD
Alfentanil—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00178	0.0115	CcSEcCtD
Alfentanil—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00173	0.0111	CcSEcCtD
Alfentanil—Epistaxis—Fludarabine—lymphatic system cancer	0.00171	0.011	CcSEcCtD
Alfentanil—Chills—Teniposide—lymphatic system cancer	0.00166	0.0107	CcSEcCtD
Alfentanil—Arrhythmia—Teniposide—lymphatic system cancer	0.00165	0.0106	CcSEcCtD
Alfentanil—Visual impairment—Fludarabine—lymphatic system cancer	0.00157	0.0101	CcSEcCtD
Alfentanil—Agitation—Teniposide—lymphatic system cancer	0.00148	0.00952	CcSEcCtD
Alfentanil—Bronchospasm—Bleomycin—lymphatic system cancer	0.00146	0.00943	CcSEcCtD
Alfentanil—Chills—Fludarabine—lymphatic system cancer	0.00146	0.00939	CcSEcCtD
Alfentanil—Arrhythmia—Fludarabine—lymphatic system cancer	0.00145	0.00935	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00144	0.0093	CcSEcCtD
Alfentanil—Hypertension—Teniposide—lymphatic system cancer	0.00139	0.00895	CcSEcCtD
Alfentanil—Cardiac arrest—Vincristine—lymphatic system cancer	0.00136	0.00879	CcSEcCtD
Alfentanil—Confusional state—Teniposide—lymphatic system cancer	0.00132	0.00853	CcSEcCtD
Alfentanil—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00131	0.00845	CcSEcCtD
Alfentanil—Agitation—Fludarabine—lymphatic system cancer	0.0013	0.00837	CcSEcCtD
Alfentanil—Tachycardia—Teniposide—lymphatic system cancer	0.00128	0.00826	CcSEcCtD
Alfentanil—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00127	0.00818	CcSEcCtD
Alfentanil—Pruritus—Mechlorethamine—lymphatic system cancer	0.00126	0.00812	CcSEcCtD
Alfentanil—Cough—Fludarabine—lymphatic system cancer	0.00123	0.00795	CcSEcCtD
Alfentanil—Hypotension—Teniposide—lymphatic system cancer	0.00123	0.0079	CcSEcCtD
Alfentanil—Convulsion—Fludarabine—lymphatic system cancer	0.00123	0.00789	CcSEcCtD
Alfentanil—Confusional state—Fludarabine—lymphatic system cancer	0.00116	0.0075	CcSEcCtD
Alfentanil—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00115	0.00743	CcSEcCtD
Alfentanil—Vomiting—Mechlorethamine—lymphatic system cancer	0.00113	0.00729	CcSEcCtD
Alfentanil—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00113	0.00729	CcSEcCtD
Alfentanil—Apnoea—Methotrexate—lymphatic system cancer	0.00113	0.00729	CcSEcCtD
Alfentanil—Rash—Mechlorethamine—lymphatic system cancer	0.00112	0.00723	CcSEcCtD
Alfentanil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00112	0.00723	CcSEcCtD
Alfentanil—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00112	0.00719	CcSEcCtD
Alfentanil—Feeling abnormal—Teniposide—lymphatic system cancer	0.00108	0.00697	CcSEcCtD
Alfentanil—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00108	0.00694	CcSEcCtD
Alfentanil—Chills—Bleomycin—lymphatic system cancer	0.00107	0.00688	CcSEcCtD
Alfentanil—Nausea—Mechlorethamine—lymphatic system cancer	0.00106	0.00682	CcSEcCtD
Alfentanil—Urticaria—Teniposide—lymphatic system cancer	0.00104	0.00672	CcSEcCtD
Alfentanil—Body temperature increased—Teniposide—lymphatic system cancer	0.00104	0.00669	CcSEcCtD
Alfentanil—Erythema—Bleomycin—lymphatic system cancer	0.00104	0.00668	CcSEcCtD
Alfentanil—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00102	0.00658	CcSEcCtD
Alfentanil—Visual impairment—Carmustine—lymphatic system cancer	0.001	0.00645	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000997	0.00642	CcSEcCtD
Alfentanil—Fatigue—Fludarabine—lymphatic system cancer	0.000996	0.00641	CcSEcCtD
Alfentanil—Pain—Fludarabine—lymphatic system cancer	0.000987	0.00636	CcSEcCtD
Alfentanil—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000984	0.00634	CcSEcCtD
Alfentanil—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000976	0.00628	CcSEcCtD
Alfentanil—Eye disorder—Carmustine—lymphatic system cancer	0.000972	0.00626	CcSEcCtD
Alfentanil—Hypersensitivity—Teniposide—lymphatic system cancer	0.000968	0.00623	CcSEcCtD
Alfentanil—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000952	0.00613	CcSEcCtD
Alfentanil—Asthenia—Teniposide—lymphatic system cancer	0.000943	0.00607	CcSEcCtD
Alfentanil—Pruritus—Teniposide—lymphatic system cancer	0.00093	0.00598	CcSEcCtD
Alfentanil—Arrhythmia—Carmustine—lymphatic system cancer	0.000929	0.00598	CcSEcCtD
Alfentanil—Cardiac disorder—Vincristine—lymphatic system cancer	0.000922	0.00593	CcSEcCtD
Alfentanil—Body temperature increased—Fludarabine—lymphatic system cancer	0.000913	0.00588	CcSEcCtD
Alfentanil—Mental disorder—Carmustine—lymphatic system cancer	0.000911	0.00587	CcSEcCtD
Alfentanil—Erythema—Carmustine—lymphatic system cancer	0.000906	0.00583	CcSEcCtD
Alfentanil—Cough—Bleomycin—lymphatic system cancer	0.000905	0.00583	CcSEcCtD
Alfentanil—Angiopathy—Vincristine—lymphatic system cancer	0.000901	0.0058	CcSEcCtD
Alfentanil—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000895	0.00576	CcSEcCtD
Alfentanil—Mental disorder—Vincristine—lymphatic system cancer	0.00087	0.0056	CcSEcCtD
Alfentanil—Chills—Mitoxantrone—lymphatic system cancer	0.000868	0.00559	CcSEcCtD
Alfentanil—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000864	0.00556	CcSEcCtD
Alfentanil—Confusional state—Bleomycin—lymphatic system cancer	0.000854	0.0055	CcSEcCtD
Alfentanil—Vision blurred—Carmustine—lymphatic system cancer	0.000853	0.00549	CcSEcCtD
Alfentanil—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000851	0.00548	CcSEcCtD
Alfentanil—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000847	0.00545	CcSEcCtD
Alfentanil—Erythema—Mitoxantrone—lymphatic system cancer	0.000842	0.00542	CcSEcCtD
Alfentanil—Vomiting—Teniposide—lymphatic system cancer	0.000835	0.00538	CcSEcCtD
Alfentanil—Agitation—Carmustine—lymphatic system cancer	0.000832	0.00536	CcSEcCtD
Alfentanil—Asthenia—Fludarabine—lymphatic system cancer	0.000828	0.00533	CcSEcCtD
Alfentanil—Rash—Teniposide—lymphatic system cancer	0.000828	0.00533	CcSEcCtD
Alfentanil—Dermatitis—Teniposide—lymphatic system cancer	0.000828	0.00533	CcSEcCtD
Alfentanil—Headache—Teniposide—lymphatic system cancer	0.000823	0.0053	CcSEcCtD
Alfentanil—Pruritus—Fludarabine—lymphatic system cancer	0.000817	0.00526	CcSEcCtD
Alfentanil—Agitation—Vincristine—lymphatic system cancer	0.000794	0.00511	CcSEcCtD
Alfentanil—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000793	0.00511	CcSEcCtD
Alfentanil—Hypotension—Bleomycin—lymphatic system cancer	0.000791	0.00509	CcSEcCtD
Alfentanil—Convulsion—Carmustine—lymphatic system cancer	0.000785	0.00505	CcSEcCtD
Alfentanil—Hypertension—Carmustine—lymphatic system cancer	0.000782	0.00503	CcSEcCtD
Alfentanil—Nausea—Teniposide—lymphatic system cancer	0.00078	0.00502	CcSEcCtD
Alfentanil—Convulsion—Vincristine—lymphatic system cancer	0.000749	0.00482	CcSEcCtD
Alfentanil—Hypertension—Vincristine—lymphatic system cancer	0.000746	0.0048	CcSEcCtD
Alfentanil—Confusional state—Carmustine—lymphatic system cancer	0.000745	0.0048	CcSEcCtD
Alfentanil—Visual disturbance—Methotrexate—lymphatic system cancer	0.000735	0.00473	CcSEcCtD
Alfentanil—Cough—Mitoxantrone—lymphatic system cancer	0.000735	0.00473	CcSEcCtD
Alfentanil—Vomiting—Fludarabine—lymphatic system cancer	0.000734	0.00473	CcSEcCtD
Alfentanil—Convulsion—Mitoxantrone—lymphatic system cancer	0.000729	0.0047	CcSEcCtD
Alfentanil—Rash—Fludarabine—lymphatic system cancer	0.000728	0.00469	CcSEcCtD
Alfentanil—Dermatitis—Fludarabine—lymphatic system cancer	0.000727	0.00468	CcSEcCtD
Alfentanil—Hypertension—Mitoxantrone—lymphatic system cancer	0.000727	0.00468	CcSEcCtD
Alfentanil—Pain—Bleomycin—lymphatic system cancer	0.000724	0.00466	CcSEcCtD
Alfentanil—Headache—Fludarabine—lymphatic system cancer	0.000723	0.00466	CcSEcCtD
Alfentanil—Tachycardia—Carmustine—lymphatic system cancer	0.000721	0.00464	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00072	0.00463	CcSEcCtD
Alfentanil—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000705	0.00454	CcSEcCtD
Alfentanil—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000698	0.00449	CcSEcCtD
Alfentanil—Confusional state—Mitoxantrone—lymphatic system cancer	0.000693	0.00446	CcSEcCtD
Alfentanil—Nervous system disorder—Vincristine—lymphatic system cancer	0.000692	0.00445	CcSEcCtD
Alfentanil—Hypotension—Carmustine—lymphatic system cancer	0.000691	0.00445	CcSEcCtD
Alfentanil—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000687	0.00442	CcSEcCtD
Alfentanil—Nausea—Fludarabine—lymphatic system cancer	0.000686	0.00442	CcSEcCtD
Alfentanil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000682	0.00439	CcSEcCtD
Alfentanil—Urticaria—Bleomycin—lymphatic system cancer	0.000673	0.00433	CcSEcCtD
Alfentanil—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000671	0.00432	CcSEcCtD
Alfentanil—Body temperature increased—Bleomycin—lymphatic system cancer	0.000669	0.00431	CcSEcCtD
Alfentanil—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000667	0.0043	CcSEcCtD
Alfentanil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000664	0.00428	CcSEcCtD
Alfentanil—Hypotension—Vincristine—lymphatic system cancer	0.000659	0.00424	CcSEcCtD
Alfentanil—Somnolence—Carmustine—lymphatic system cancer	0.000657	0.00423	CcSEcCtD
Alfentanil—Hypotension—Mitoxantrone—lymphatic system cancer	0.000642	0.00413	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000638	0.00411	CcSEcCtD
Alfentanil—Pain—Carmustine—lymphatic system cancer	0.000632	0.00407	CcSEcCtD
Alfentanil—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000624	0.00402	CcSEcCtD
Alfentanil—Somnolence—Mitoxantrone—lymphatic system cancer	0.000611	0.00393	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000609	0.00392	CcSEcCtD
Alfentanil—Feeling abnormal—Carmustine—lymphatic system cancer	0.000609	0.00392	CcSEcCtD
Alfentanil—Fatigue—Vincristine—lymphatic system cancer	0.000608	0.00392	CcSEcCtD
Alfentanil—Asthenia—Bleomycin—lymphatic system cancer	0.000607	0.00391	CcSEcCtD
Alfentanil—Pain—Vincristine—lymphatic system cancer	0.000603	0.00388	CcSEcCtD
Alfentanil—Pruritus—Bleomycin—lymphatic system cancer	0.000599	0.00386	CcSEcCtD
Alfentanil—Fatigue—Mitoxantrone—lymphatic system cancer	0.000592	0.00381	CcSEcCtD
Alfentanil—Pain—Mitoxantrone—lymphatic system cancer	0.000588	0.00378	CcSEcCtD
Alfentanil—Body temperature increased—Carmustine—lymphatic system cancer	0.000584	0.00376	CcSEcCtD
Alfentanil—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000566	0.00364	CcSEcCtD
Alfentanil—Body temperature increased—Vincristine—lymphatic system cancer	0.000558	0.00359	CcSEcCtD
Alfentanil—Urticaria—Mitoxantrone—lymphatic system cancer	0.000546	0.00351	CcSEcCtD
Alfentanil—Hypersensitivity—Carmustine—lymphatic system cancer	0.000544	0.00351	CcSEcCtD
Alfentanil—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000543	0.0035	CcSEcCtD
Alfentanil—Vomiting—Bleomycin—lymphatic system cancer	0.000538	0.00347	CcSEcCtD
Alfentanil—Drowsiness—Methotrexate—lymphatic system cancer	0.000537	0.00346	CcSEcCtD
Alfentanil—Rash—Bleomycin—lymphatic system cancer	0.000534	0.00344	CcSEcCtD
Alfentanil—Dermatitis—Bleomycin—lymphatic system cancer	0.000533	0.00343	CcSEcCtD
Alfentanil—Asthenia—Carmustine—lymphatic system cancer	0.00053	0.00341	CcSEcCtD
Alfentanil—Hypersensitivity—Vincristine—lymphatic system cancer	0.00052	0.00335	CcSEcCtD
Alfentanil—Epistaxis—Methotrexate—lymphatic system cancer	0.000506	0.00326	CcSEcCtD
Alfentanil—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000506	0.00326	CcSEcCtD
Alfentanil—Asthenia—Vincristine—lymphatic system cancer	0.000506	0.00326	CcSEcCtD
Alfentanil—Nausea—Bleomycin—lymphatic system cancer	0.000503	0.00324	CcSEcCtD
Alfentanil—Asthenia—Mitoxantrone—lymphatic system cancer	0.000493	0.00317	CcSEcCtD
Alfentanil—Dizziness—Carmustine—lymphatic system cancer	0.000489	0.00315	CcSEcCtD
Alfentanil—Vomiting—Carmustine—lymphatic system cancer	0.00047	0.00303	CcSEcCtD
Alfentanil—Dizziness—Vincristine—lymphatic system cancer	0.000467	0.003	CcSEcCtD
Alfentanil—Rash—Carmustine—lymphatic system cancer	0.000466	0.003	CcSEcCtD
Alfentanil—Dermatitis—Carmustine—lymphatic system cancer	0.000466	0.003	CcSEcCtD
Alfentanil—Visual impairment—Methotrexate—lymphatic system cancer	0.000464	0.00299	CcSEcCtD
Alfentanil—Headache—Carmustine—lymphatic system cancer	0.000463	0.00298	CcSEcCtD
Alfentanil—Eye disorder—Methotrexate—lymphatic system cancer	0.00045	0.0029	CcSEcCtD
Alfentanil—Vomiting—Vincristine—lymphatic system cancer	0.000449	0.00289	CcSEcCtD
Alfentanil—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000447	0.00288	CcSEcCtD
Alfentanil—Rash—Vincristine—lymphatic system cancer	0.000445	0.00286	CcSEcCtD
Alfentanil—Dermatitis—Vincristine—lymphatic system cancer	0.000444	0.00286	CcSEcCtD
Alfentanil—Headache—Vincristine—lymphatic system cancer	0.000442	0.00285	CcSEcCtD
Alfentanil—Nausea—Carmustine—lymphatic system cancer	0.000439	0.00283	CcSEcCtD
Alfentanil—Angiopathy—Methotrexate—lymphatic system cancer	0.000437	0.00281	CcSEcCtD
Alfentanil—Vomiting—Mitoxantrone—lymphatic system cancer	0.000437	0.00281	CcSEcCtD
Alfentanil—Immune system disorder—Methotrexate—lymphatic system cancer	0.000435	0.0028	CcSEcCtD
Alfentanil—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000434	0.0028	CcSEcCtD
Alfentanil—Rash—Mitoxantrone—lymphatic system cancer	0.000433	0.00279	CcSEcCtD
Alfentanil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000433	0.00279	CcSEcCtD
Alfentanil—Chills—Methotrexate—lymphatic system cancer	0.000432	0.00278	CcSEcCtD
Alfentanil—Headache—Mitoxantrone—lymphatic system cancer	0.00043	0.00277	CcSEcCtD
Alfentanil—Mental disorder—Methotrexate—lymphatic system cancer	0.000422	0.00272	CcSEcCtD
Alfentanil—Erythema—Methotrexate—lymphatic system cancer	0.000419	0.0027	CcSEcCtD
Alfentanil—Nausea—Vincristine—lymphatic system cancer	0.000419	0.0027	CcSEcCtD
Alfentanil—Nausea—Mitoxantrone—lymphatic system cancer	0.000408	0.00263	CcSEcCtD
Alfentanil—Vision blurred—Methotrexate—lymphatic system cancer	0.000395	0.00254	CcSEcCtD
Alfentanil—Cough—Methotrexate—lymphatic system cancer	0.000366	0.00236	CcSEcCtD
Alfentanil—Convulsion—Methotrexate—lymphatic system cancer	0.000363	0.00234	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000355	0.00228	CcSEcCtD
Alfentanil—Confusional state—Methotrexate—lymphatic system cancer	0.000345	0.00222	CcSEcCtD
Alfentanil—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000342	0.0022	CcSEcCtD
Alfentanil—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000336	0.00216	CcSEcCtD
Alfentanil—Skin disorder—Methotrexate—lymphatic system cancer	0.000332	0.00214	CcSEcCtD
Alfentanil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000331	0.00213	CcSEcCtD
Alfentanil—Hypotension—Methotrexate—lymphatic system cancer	0.00032	0.00206	CcSEcCtD
Alfentanil—Somnolence—Methotrexate—lymphatic system cancer	0.000304	0.00196	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000296	0.0019	CcSEcCtD
Alfentanil—Fatigue—Methotrexate—lymphatic system cancer	0.000295	0.0019	CcSEcCtD
Alfentanil—Pain—Methotrexate—lymphatic system cancer	0.000293	0.00188	CcSEcCtD
Alfentanil—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000282	0.00182	CcSEcCtD
Alfentanil—Urticaria—Methotrexate—lymphatic system cancer	0.000272	0.00175	CcSEcCtD
Alfentanil—Body temperature increased—Methotrexate—lymphatic system cancer	0.000271	0.00174	CcSEcCtD
Alfentanil—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000252	0.00162	CcSEcCtD
Alfentanil—Asthenia—Methotrexate—lymphatic system cancer	0.000246	0.00158	CcSEcCtD
Alfentanil—Pruritus—Methotrexate—lymphatic system cancer	0.000242	0.00156	CcSEcCtD
Alfentanil—Dizziness—Methotrexate—lymphatic system cancer	0.000226	0.00146	CcSEcCtD
Alfentanil—Vomiting—Methotrexate—lymphatic system cancer	0.000218	0.0014	CcSEcCtD
Alfentanil—Rash—Methotrexate—lymphatic system cancer	0.000216	0.00139	CcSEcCtD
Alfentanil—Dermatitis—Methotrexate—lymphatic system cancer	0.000216	0.00139	CcSEcCtD
Alfentanil—Headache—Methotrexate—lymphatic system cancer	0.000214	0.00138	CcSEcCtD
Alfentanil—Nausea—Methotrexate—lymphatic system cancer	0.000203	0.00131	CcSEcCtD
